Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Maria L Agostini"'
Autor:
Jennifer Gribble, Laura J Stevens, Maria L Agostini, Jordan Anderson-Daniels, James D Chappell, Xiaotao Lu, Andrea J Pruijssers, Andrew L Routh, Mark R Denison
Publikováno v:
PLoS Pathogens, Vol 17, Iss 1, p e1009226 (2021)
Recombination is proposed to be critical for coronavirus (CoV) diversity and emergence of SARS-CoV-2 and other zoonotic CoVs. While RNA recombination is required during normal CoV replication, the mechanisms and determinants of CoV recombination are
Externí odkaz:
https://doaj.org/article/526fcaa34c3442458c7bf131f0326706
Autor:
Samantha L. Grimes, Young J. Choi, Anoosha Banerjee, Gabriel Small, Jordan Anderson-Daniels, Jennifer Gribble, Andrea J. Pruijssers, Maria L. Agostini, Alexandra Abu-Shmais, Xiaotao Lu, Seth A. Darst, Elizabeth Campbell, Mark R. Denison
Publikováno v:
mBio, Vol 14, Iss 4 (2023)
ABSTRACT Coronaviruses (CoVs) encode nonstructural proteins 1–16 (nsps 1–16) which form replicase complexes that mediate viral RNA synthesis. Remdesivir (RDV) is an adenosine nucleoside analog antiviral that inhibits CoV RNA synthesis. RDV resist
Externí odkaz:
https://doaj.org/article/351eda1dc8534b2e94fffb7f9053450a
Autor:
Adrienne E. Shapiro, Elias Sarkis, Jude Acloque, Almena Free, Yaneicy Gonzalez-Rojas, Rubaba Hussain, Erick Juarez, Jaynier Moya, Naval Parikh, David Inman, Deborah Cebrik, Ahmed Nader, Nadia Noormohamed, Qianwen Wang, Andrew Skingsley, Daren Austin, Amanda Peppercorn, Maria L. Agostini, Sergio Parra, Sophia Chow, Erik Mogalian, Phillip S. Pang, David K. Hong, Jennifer E. Sager, Wendy W. Yeh, Elizabeth L. Alexander, Leah A. Gaffney, Anita Kohli
BackgroundConvenient administration of coronavirus disease 2019 (COVID-19) treatment in community settings is desirable. Sotrovimab is a pan-sarbecovirus dual-action monoclonal antibody formulated for intravenous (IV) or intramuscular (IM) administra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6eb08d2911a70bce8dc0f30cdc3cae2d
https://doi.org/10.1101/2023.03.21.23287410
https://doi.org/10.1101/2023.03.21.23287410
Autor:
Maria L Agostini, Gretja Schnell, Julia di Iulio, Anita Kohli, Adrienne E Shapiro, Elias H Sarkis, Dave Inman, Amanda Peppercorn, Andrew Skingsley, Leah A Gaffney, Melissa Aldinger, Christy M Hebner, Andrea L Cathcart
Publikováno v:
Open Forum Infectious Diseases. 9
Background Sotrovimab (VIR-7831) is an engineered human monoclonal antibody targeting a conserved region of the SARS-CoV-2 spike protein; it has been shown to have a favorable safety profile and be effective for early treatment of high-risk COVID-19
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eaee9d60bad49ab049db89a91026ce55
https://doi.org/10.1093/ofid/ofac492.988
https://doi.org/10.1093/ofid/ofac492.988
Autor:
Jason A. Wojcechowskyj, Marcel Meury, Dora Pinto, Exequiel Dellota, Fabio Benigni, Jesse D. Bloom, M. Alejandra Tortorici, Florian A. Lempp, Anna De Marco, Josh Dillen, Christy M. Hebner, Amin Addetia, Fabrizia Zatta, Laura E. Rosen, Elisabetta Cameroni, Nadine Czudnochowski, Amalio Telenti, Johan Neyts, Stefano Jaconi, Allison J. Greaney, Zhuoming Liu, Patrick Hernandez, John E. Bowen, Roberta Marzi, Jiayi Zhou, Maria L. Agostini, Hannah Kaiser, William G. Glass, Rana Abdelnabi, Ivy Zhang, Tristan I. Croll, Adam S. Dingens, Gyorgy Snell, Shi-Yan Caroline Foo, Davide Corti, Luca Piccoli, Martin Montiel-Ruiz, David Veesler, Sean P. J. Whelan, Gloria Lombardo, Herbert W. Virgin, Martina Beltramello, Colin Havenar-Daughton, Spencer Stumpf, Tyler N. Starr, Michael P. Housley, Jessica Bassi, John D. Chodera, Katja Culap, Nicole Sprugasci, Julia di Iulio, Chiara Silacci-Fregni, Matteo Samuele Pizzuto, Alexandra C. Walls, Young-Jun Park, Jay C. Nix, Heather Tucker
Publikováno v:
Nature
Nature, vol 597, iss 7874
Nature, vol 597, iss 7874
An ideal therapeutic anti-SARS-CoV-2 antibody would resist viral escape1–3, have activity against diverse sarbecoviruses4–7, and be highly protective through viral neutralization8–11 and effector functions12,13. Understanding how these properti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea33aa8d0b103b0c5bd075c01c53fa5a
https://europepmc.org/articles/PMC9282883/
https://europepmc.org/articles/PMC9282883/
Autor:
Andrea L. Cathcart, Colin Havenar-Daughton, Florian A. Lempp, Daphne Ma, Michael A. Schmid, Maria L. Agostini, Barbara Guarino, Julia Di iulio, Laura E. Rosen, Heather Tucker, Joshua Dillen, Sambhavi Subramanian, Barbara Sloan, Siro Bianchi, Dora Pinto, Christian Saliba, Katja Culap, Jason A Wojcechowskyj, Julia Noack, Jiayi Zhou, Hannah Kaiser, Sooyoung Lee, Nisar Farhat, Arthur Chase, Martin Montiel-Ruiz, Exequiel Dellota, Arnold Park, Roberto Spreafico, Anna Sahakyan, Elvin J. Lauron, Nadine Czudnochowski, Elisabetta Cameroni, Sarah Ledoux, Yoshihiro Kawaoka, Adam Werts, Christophe Colas, Leah Soriaga, Amalio Telenti, Lisa A. Purcell, Seungmin Hwang, Gyorgy Snell, Herbert W. Virgin, Davide Corti, Christy M. Hebner
VIR-7831 and VIR-7832 are dual action monoclonal antibodies (mAbs) targeting the spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). VIR-7831 and VIR-7832 were derived from a parent antibody (S309) isolated from memory
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a80fd146e1b2084c931712710b2229b0
https://doi.org/10.1101/2021.03.09.434607
https://doi.org/10.1101/2021.03.09.434607
Autor:
Laura J. Stevens, Mark R. Denison, Alexandra Schäfer, James D. Chappell, Bin Ma, David R. Martinez, Maria L. Agostini, Jason K. Perry, Rachel L. Graham, John P. Bilello, Jared Pitts, Kendra Gully, Danielle Porter, Ariane J. Brown, Eisuke Murakami, Venice Du Pont, Timothy P. Sheahan, Sarah R. Leist, Kenneth H. Dinnon, Darius Babusis, Boyd Yount, Lisa E. Gralinksi, Tia M. Hughes, Ralph S. Baric, Joy Y. Feng, Xiaotao Lu, Andrea J. Pruijssers, Tomas Cihlar, Amelia S. George
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in 2019 as the causative agent of the novel pandemic viral disease COVID-19. With no approved therapies, this pandemic illustrates the urgent need for safe, broad-spectrum antiviral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55d39047893773d908934086bdfb9634
Autor:
Laura J. Stevens, Xiaotao Lu, James D. Chappell, Joy Y. Feng, Jared Pitts, Rachel L. Graham, Sarah R. Leist, Alexandra Schäfer, Kenneth H. Dinnon, Tia M. Hughes, Amelia S. George, Venice Du Pont, Ralph S. Baric, David R. Martinez, Maria L. Agostini, Mark R. Denison, Andrea J. Pruijssers, Tomas Cihlar, Eisuke Murakami, Ariane J. Brown, Jason K. Perry, Boyd Yount, John P. Bilello, Danielle P. Porter, Bin Ma, Kendra Gully, Timothy P. Sheahan, Darius Babusis, Lisa E. Gralinksi
Publikováno v:
bioRxiv
Cell Reports
Cell Reports
Summary Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the novel viral disease COVID-19. With no approved therapies, this pandemic illustrates the urgent need for broad-spectrum antiviral countermeasures agains
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a17f99cb84e38f6f1dee1da759e5e1c5
https://pubmed.ncbi.nlm.nih.gov/32511392
https://pubmed.ncbi.nlm.nih.gov/32511392
Autor:
Maria L. Agostini, Ronald Swanstrom, Natalie J. Thornburg, Sarah R. Leist, Kenneth H. Dinnon, Gregory R. Bluemling, Andrea J. Pruijssers, Alexandra Schaefer, Azaibi Tamin, Stephanie A. Montgomery, Ariane J. Brown, James D. Chappell, Amy C. Sims, Rachel L. Graham, George R. Painter, Manohar Saindane, Shuntai Zhou, Jennifer L Harcourt, Timothy P. Sheahan, Ralph S. Baric, Michael G. Natchus, Alexander A. Kolykhalov, Mark R. Denison, Collin S. Hill
Coronaviruses (CoVs) traffic frequently between species resulting in novel disease outbreaks, most recently exemplified by the newly emerged SARS-CoV-2. Herein, we show that the ribonucleoside analog β-D-N4-hydroxycytidine (NHC, EIDD-1931) has broad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97916e086b88bd18f3c8d1a0a88d1cb3
Autor:
James D. Chappell, Amy C. Sims, Gregory R. Bluemling, Jennifer Gribble, Maria L. Agostini, Timothy P. Sheahan, Mark A. Lockwood, Ralph S. Baric, Erica L. Andres, Michael G. Natchus, George R. Painter, Xiaotao Lu, Manohar Saindane, Andrea J. Pruijssers, Mark R. Denison, Alexander A. Kolykhalov
Publikováno v:
Journal of Virology
Coronaviruses (CoVs) have emerged from animal reservoirs to cause severe and lethal disease in humans, but there are currently no FDA-approved antivirals to treat the infections One class of antiviral compounds, nucleoside analogues, mimics naturally
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62ebdd71ba2959b277f4b3ed92a7c09c
https://doi.org/10.1128/jvi.01348-19
https://doi.org/10.1128/jvi.01348-19